In a patient with colon cancer who has a positive Signatera (circulating tumor DNA) result after curative‑intent treatment but a negative imaging scan, what is the recommended management?

Management of Positive Signatera with Negative Imaging in Colon Cancer

In a patient with colon cancer who has a positive Signatera (ctDNA) result after curative-intent treatment but negative imaging, you should intensify imaging surveillance with repeat scans every 3 months and consider the patient at very high risk for recurrence, but current evidence does not support initiating systemic chemotherapy based on ctDNA positivity alone without radiographic confirmation of disease.

Understanding the Clinical Scenario

This situation represents molecular residual disease (MRD) detection—where circulating tumor DNA signals the presence of microscopic cancer that imaging cannot yet visualize. The Signatera assay is a tumor-informed, personalized ctDNA test that tracks patient-specific mutations, offering high specificity for detecting minimal residual disease 1, 2.

What the Evidence Shows About ctDNA Positivity

Prognostic Significance:

• Postoperative ctDNA positivity is one of the strongest known predictors of recurrence in colon cancer, with ctDNA-positive patients experiencing dramatically worse recurrence-free survival compared to ctDNA-negative patients 2, 3, 4
• ctDNA positivity typically precedes radiographic recurrence by 3-10 months, with some studies showing lead times up to 9 months 1, 2, 5
• In real-world case series, ctDNA detected recurrence before imaging in 100% of cases where both eventually became positive 1

The Critical Gap:

• While ctDNA positivity strongly predicts recurrence, there is no proven benefit from treating ctDNA-positive, imaging-negative disease with systemic chemotherapy 2, 4
• The DYNAMIC-III trial showed that escalated chemotherapy in ctDNA-positive stage III patients did not improve outcomes 4
• Recent data suggest potential benefit in specific subgroups (microsatellite stable stage II disease in CIRCULATE trial), but the primary endpoint was not statistically significant 4

Recommended Management Algorithm

Immediate Actions:

1. Confirm ctDNA Positivity:

   • Repeat Signatera testing in 4-6 weeks to confirm persistent positivity (rule out transient shedding or false positive)
   • Document the MTM/ml value and trend over serial measurements 1

2. Intensified Imaging Surveillance:

   • Obtain immediate reflex imaging with contrast-enhanced CT chest/abdomen/pelvis 6
   • If negative, repeat imaging every 3 months (rather than standard 6-month intervals) until either:
     • Disease becomes radiographically evident, OR
     • ctDNA clears spontaneously (occurs in ~15-20% of cases) 6
   • Consider PET-CT if conventional imaging remains negative but ctDNA persists, as it may detect occult disease earlier 7

3. Colonoscopy:

   • Perform colonoscopy to exclude anastomotic or metachronous colorectal recurrence 8

Treatment Decision Framework:

DO NOT initiate systemic chemotherapy based solely on ctDNA positivity without radiographic confirmation 2, 4. The rationale:

• No randomized trial has demonstrated that treating molecular-only recurrence improves disease-free or overall survival
• In one retrospective cohort, only 1.6% of surveilled patients achieved durable disease-free status after ctDNA-prompted intervention 6
• Risk of overtreatment with chemotherapy toxicity without proven benefit

DO consider systemic therapy when:

• Imaging confirms oligometastatic disease amenable to curative-intent metastasectomy (liver, lung) followed by adjuvant chemotherapy 8, 9, 1
• Serial ctDNA shows rising levels with increasing MTM/ml values, suggesting active disease progression 1

Surgical Intervention:

If imaging eventually reveals isolated, resectable metastases:

• Pursue curative-intent metastasectomy (liver or lung resection) 8, 9, 1
• Post-metastasectomy ctDNA clearance is associated with improved outcomes 1
• Follow with adjuvant chemotherapy per standard guidelines for metastatic disease 9

Critical Pitfalls to Avoid

1. Premature Treatment Escalation:

   • Do not reflexively start chemotherapy for ctDNA positivity alone—this represents unvalidated practice that may cause harm without benefit 2, 4

2. Inadequate Follow-up:

   • Standard 6-month imaging intervals are insufficient for ctDNA-positive patients; disease may progress to unresectable status during this window 1, 5

3. Ignoring Spontaneous Clearance:

   • Approximately 15-20% of ctDNA-positive patients experience spontaneous clearance without intervention 6
   • Serial monitoring distinguishes transient from persistent positivity

4. False Positives from Clonal Hematopoiesis:

   • Tumor-informed assays like Signatera minimize but do not eliminate false positives from clonal hematopoiesis of indeterminate potential (CHIP) 10
   • Clinical context and serial measurements help distinguish true recurrence

Nuances in the Evidence

The guidelines provided 8, 11, 8, 11, 12 predate the ctDNA era (2001-2021) and focus on CEA monitoring and conventional imaging. CEA elevation warrants further evaluation but does not justify initiating therapy without radiographic confirmation 11—a principle that extends to ctDNA monitoring.

More recent research 1, 2, 3, 6, 5, 4, 10 establishes ctDNA as superior to CEA for early recurrence detection but emphasizes that prognostic value does not equal treatment-selection utility. The DYNAMIC trial 3 successfully used ctDNA to de-escalate treatment in stage II disease, but escalation trials (DYNAMIC-III) failed to show benefit 4.

The current evidence supports ctDNA as a surveillance tool to trigger earlier imaging and enable curative-intent surgery when feasible, but not as a standalone indication for systemic therapy 2, 6, 4, 10.